Skip to main content
Fig. 15 | BMC Cancer

Fig. 15

From: Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Fig. 15

Forest Plot of Progression-free Survival Treatment Comparison: HER2– Subgroup Analysis. Estimates derived only from indirect comparisons shown in black box. Included references: Study 301 (Twelves 2016), CA163–046 (Hortobagyi 2010; Thomas 2007), Sparano 2010, Pallis 2012. Abbreviations: CAP = capecitabine; CrI = credible interval; ERI = eribulin; GEM = gemcitabine; HER2 = human epidermal growth factor receptor 2; IXA = ixabepilone; VIN = vinorelbine

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us